In July 2005, Declan Hamill joined Innovative Medicines Canada, the national association representing the voice of Canada’s innovative pharmaceutical industry.
Mr. Hamill provides advice and counsel regarding legal, trade and compliance issues. He serves as the in-house resource to provide expertise and advice on recent jurisprudence and other legal and IP developments affecting the industry. In September 2016, Mr. Hamill assumed additional responsibility for the regulatory and policy functions at Innovative Medicines Canada.
Mr. Hamill has appeared before several Canadian government bodies and committees, including the House of Commons Industry, Science and Technology Committee, and the Standing Committee on International Trade.
Mr. Hamill is also the Chair of the Board of Directors of the Stem Cell Network, a Canadian not-for-profit that supports three main objectives: stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and supporting the knowledge mobilization and transfer of stem cell and regenerative medicine research.